Scisparc announces enrollment of first patient for its clinical trial for children with autism spectrum disorder

Tel aviv, israel, march 08, 2024 (globe newswire) -- scisparc ltd. (nasdaq: sprc) ("company" or "scisparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, today announced that the first patient has been enrolled in the company's clinical trial assessing the efficacy and safety of sci-210 for the treatment of children with autism spectrum disorder (“asd”) between the ages of 5 and 18.
SPRC Ratings Summary
SPRC Quant Ranking